| 1 |
33737682 | Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer. | 2021 Mar 18 |
2 |
| 2 |
34728668 | Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study. | 2021 Nov 2 |
1 |
| 3 |
32354934 | Bevacizumab as First-line Treatment for HER2-negative Advanced Breast Cancer: Paclitaxel plus Bevacizumab Versus Other Chemotherapy. | 2020 May-Jun |
2 |